Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rolston, K. V. I.
Right arrow Articles by Bodey, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rolston, K. V. I.
Right arrow Articles by Bodey, G. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1986) 18, 159-162
© 1986 The British Society for Antimicrobial Chemotherapy

research-article

In-vitro activity of Sch 34343, a new penam, against Gram-positive isolates from cancer patients

Kenneth V. I. Rolston, Maria Elena Alvarez, Jennifer F. Hoy, Helen C. Alderman, Dah Hsi Ho and Gerald P. Bodey

Section of Infectious Diseases, Department of Internal Medicine, The University of Texas M. D. Anderson Hospital and Tumor Institute 6723 Bertner Avenue, Houston, Texas 77030, U.S.A.

accepted 10 February 1986

The in-vitro activity of Sch 34343, a new penam antibiotic, was tested against 257 Gram-positive isolates from cancer patients, and compared with that of imipenem and amifloxacin. Sch 34343 was extremely active against ß-haemolytic streptococci (Lancefield groups A, B and G) with MIC90s ranging from 0.025 to 0.05 mg/l. It was also active against methicillin-susceptible Staphylococcus aureus and had variable activity against coagulase-negative staphylococci. MIC90 for Listeria monocytogenes was 0.78 mg/l and 84% of enterococcal isolates were inhibited by 6.25 mg/l.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A.-M. Tarkkanen, T. Heinonen, R. Jogi, S. Mentula, M. E. van der Rest, C. J. Donskey, T. Kemppainen, K. Gurbanov, and C. E. Nord
P1A Recombinant {beta}-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2455 - 2462.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Harmoinen, S. Mentula, M. Heikkila, M. van der Rest, P. J. Rajala-Schultz, C. J. Donskey, R. Frias, P. Koski, N. Wickstrand, H. Jousimies-Somer, et al.
Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance
Antimicrob. Agents Chemother., January 1, 2004; 48(1): 75 - 79.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Freeman, F. J. O'Neill, and M. H. Wilcox
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut
J. Antimicrob. Chemother., July 1, 2003; 52(1): 96 - 102.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.